Acute Liver Failure Market - Top Companies and Manufacturers

  • Report ID: 5770
  • Published Date: Mar 01, 2024
  • Report Format: PDF, PPT

Companies Dominating the Acute liver failure Market

    • Ipsen
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Gilead Sciences, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Bristol Myers Squibb
    • AbbVie Inc.
    • Johnson & Johnson Services Inc.
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Zydus Pharmaceuticals Inc.

Browse Key Market Insights with Data Illustration:

In the News

  • Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT announced that the New Drug Application (NDA) for investigational elafibranor has been accepted by the U.S. Food and Drug Administration (FDA). Elafibranor, an experimental oral once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, may represent the first novel second-line treatment for the uncommon cholestatic liver disease PBC in almost ten years. June 10, 2024, is the target FDA PDUFA date that is being reviewed in priority.
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced that the FDA in the United States authorized a supplemental new drug application (sNDA) for the use of Remdesivir, or Veklury®, to treat COVID-19 in patients with mild, moderate, and severe hepatic impairment. The FDA approved the sNDA without requiring dose modifications. The safety profile of Veklury, the first and only antiviral COVID-19 therapy licensed for use across all stages of liver disease, is further supported by this approval.

Author Credits:  Radhika Pawar

  • Report ID: 5770
  • Published Date: Mar 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of obesity, the increased geriatric population, and increased technological advancements in liver disease diagnosis are the major factors driving the growth of the acute liver failure market.

The market size of acute liver failure is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024 - 2036.

The major players in the market are Ipsen, Gilead Sciences, Inc., Pfizer Inc., Novartis AG, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Zydus Pharmaceuticals Inc. and others.

The liver transplant segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying